Patheon Inc. Extends Its Sterile Filling Capabilities to Include the Commercial Supply of Small Scale Specialty Products



    RESEARCH TRIANGLE PARK, NC, June 8 /CNW/ - Patheon Inc. (TSX: PTI), a
global provider of drug development and manufacturing services to the
international pharmaceutical industry, is pleased to announce that its
Swindon, UK facility has extended its aseptic vial filling capabilities to
include the commercial supply of small scale specialty products. Following
recent FDA approval at Swindon, Patheon can now provide clients with a
seamless service, where development batches and commercial product can be
supplied from the same filling line.
    The offering will be especially suited to commercial supply of niche
biological and orphan drug products where the annual volumes are small. This
new capability is now operating at Patheon's Swindon site for vial sizes
ranging from 2mL up to 30mL. In addition, the new technology allows the use of
disposable components in place of more costly stainless steel vessels. This
provides clients with an efficient filling process that overcomes challenges
posed by many large and small molecule sterile products.
    Wes Wheeler, President and CEO of Patheon Inc. stated, "We can now
produce commercial product from the same production line that is used for
Phase II and Phase III clinical batches. This allows clients to commercialize
their drugs much faster than would normally be expected."

    ABOUT PATHEON INC.

    Patheon Inc. (TSX: PTI; www.patheon.com) is a leading global provider of
contract development and manufacturing services to the pharmaceutical
industry. Patheon prides itself in providing the highest quality products and
services to more than 300 pharmaceutical and biotechnology companies.
Patheon's services range from preclinical development through the commercial
manufacturing of a wide array of dosage forms including parenteral, solid,
semi-solid and liquids. Patheon's comprehensive range of fully integrated
Pharmaceutical Development Services includes pre-formulation, formulation,
analytical development, clinical manufacturing, scale-up and
commercialization. Patheon's ability to integrate development and
manufacturing services ensures that our customers' projects are delivered on
time and meet the high standards of quality that Patheon is known for.
Patheon's integrated development and manufacturing network of 10 facilities
and 7 development centers, across North America and Europe, strives to ensure
that customer products can be launched timely and confidently anywhere in the
world.

    Caution Concerning Forward-Looking Statements This news release may
contain forward-looking statements which reflect management's expectations
regarding the Company's future growth of operations, performance (both
operational and financial) and business prospects and opportunities. These
statements are made in the context of the risks and uncertainties that are
outlined in the Company's public documents, which can be accessed on our
website at www.patheon.com or on SEDAR at www.sedar.com.

    %SEDAR: 00001700E




For further information:

For further information: Mr. Wes Wheeler, President & Chief Executive
Officer, Tel: (919) 226-3200, Email: wes.wheeler@patheon.com; Mr. Eric Evans,
Chief Financial Officer, Tel: (919) 226-3200, Email: eric.evans@patheon.com;
Mr. Norman Barras, Vice President, PDS Europe, Tel: +44(0)7725 423431, Email:
norman.barras@patheon.com

Organization Profile

Patheon Inc

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890